Navigation Links
AstraZeneca and DNDi to collaborate on drug screening for neglected tropical diseases
Date:4/12/2012

AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) today announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide. Novel drug candidates to emerge from this collaboration will bolster the drug development pipeline for new medicines urgently needed by millions of patients.

In the new partnership, AstraZeneca will provide to DNDi 15,000 compounds that have the potential for activity against leishmaniasis, Chagas disease, and sleeping sickness. The screening activities, coordinated by DNDi, will be performed at Institut Pasteur Korea (IPK). If active compounds against any of the three diseases are identified as 'hits', DNDi and AstraZeneca will jointly assess their potential as starting points for future medicines.

'As a global pharmaceutical company which conducts a significant amount of infectious disease research, AstraZeneca recognizes the urgent need to deliver new medicines for people who suffer from neglected tropical diseases. Sharing science beyond our own labs with leading organizations like DNDi is a great way to tackle these complex diseases that have gone unchecked for far too long', said Manos Perros, Head of the AstraZeneca Infection Innovative Medicines Unit.

The visceral form of leishmaniasis has one of the highest death rates of all NTDs, killing up to 60,000 people each year mainly in Africa and South Asia. The cutaneous form disables and deforms 1.5 million people throughout the Middle East and Latin America. Chagas disease infects approximately 8 million people and is the leading parasitic killer in the Americas, causing approximately 12,000 deaths each year. Sleeping sickness (human African trypanosomiasis) threatens millions in 36 countries in sub-Saharan Africa and, like the visceral form of leishmaniasis, is fatal if left untreated.

'We welcome AstraZeneca as a new partner in our ongoing efforts to access the compounds necessary to boost the development of much-needed medicines for the world's most neglected patients, including those afflicted with leishmaniasis, Chagas disease, and sleeping sickness', says Dr Bernard Pcoul, Executive Director of DNDi. 'This first agreement with AstraZeneca gives us a solid basis to build a fruitful collaboration and access promising new drug compounds for these and other neglected diseases.'

This agreement follows on the commitments announced at a landmark meeting in London on January 30, 'Uniting to Combat NTDs', where a range of public and private partners gathered in a coordinated push to support the WHO's control and eliminations goals for 10 of the 17 neglected tropical diseases (NTDs) by 2020.


'/>"/>
Contact: Oliver Yun
oyun@dndi.org
646-266-5216
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Related medicine news :

1. ECNP expresses concern at AstraZeneca neuroscience pull-out
2. AstraZeneca and UCL to collaborate to develop regenerative medicines for diabetic retinopathy
3. AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims
4. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
5. UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk
6. Kessler Foundation and USC collaborate on clinical virtual reality for disability research
7. Penn collaborates on $8 million Barretts esophagus research network
8. Young Children Collaborate Better Than Chimps
9. Scientists in Singapore and Europe to collaborate
10. MDA, Walgreens collaborate to provide flu shots at more than 8,000 locations
11. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2020)... ... June 02, 2020 , ... ... for drugs, biologics, cell and gene therapies, and consumer health products, today announced ... Lickfold succeeds John McGill, who, following a period of transition, plans to retire ...
(Date:5/28/2020)... ... May 28, 2020 , ... ... is joining the clinically integrated network (CIN) and the group purchasing organization run ... Cardiovascular Institute to establish a heart failure program at Mon Health Medical Center. ...
(Date:5/27/2020)... ... May 27, 2020 , ... Radiology Associates of Richmond (RAR), ... has aligned with the Strategic Radiology (SR) coalition of independent practices. , ... SR coalition, which has 28 member practices in 20 different states. The Richmond ...
(Date:5/26/2020)... LOS ANGELES (PRWEB) , ... May 26, 2020 , ... ... speaker, and ageless sexuality advocate Joan Price have just received the 2020 AASECT Audio ... explicit sex education film was the first of its kind to feature non-actors in ...
(Date:5/21/2020)... Minn. (PRWEB) , ... May 21, 2020 , ... ... medical device manufacturer, announces its first milestone to deliver over one million FDA-compliant ... eight weeks. Summit Medical Face Shields meet the critical need for personal protective ...
Breaking Medicine News(10 mins):
(Date:5/30/2020)... WASHINGTON (PRWEB) , ... May 29, 2020 , ... ... the following statement in response to the U.S. announcement that it will terminate ... with the Administration’s announcement that it plans to terminate its relationship with the ...
(Date:5/30/2020)... ... May 30, 2020 , ... During a crisis, the platitude “stay strong” ... - it is developed and strengthened through hardship. Recent research conducted by PsychTests.com ... in certain practices in order to stay strong in the face of adversity. It ...
(Date:5/28/2020)... ... 28, 2020 , ... When Sean Fitzgerald was in business leadership for a ... provide the physical care services needed to keep older adults in their homes, but ... Fitzgerald is pleased to be in a position to help provide those property maintenance ...
Breaking Medicine Technology: